My clinical and translational research interests currently include development of cellular therapies to enhance hematopoietic stem cell transplantation and reduce regimen-related toxicities, and development of clinical gene therapy protocols.
Dr. Goebel's clinical/translational research interests include cellular therapies to enhance hematopoietic stem cell transplantation and reduce regimen-related toxicities, and gene therapy for hematopoietic diseases.
Current efforts are focused on determining the mechanism(s) governing this engraftment defect, with the ultimate goals of: 1) using these models of HSC transduction as a tool to uncover mechanisms controlling HSC self-renewal and engraftment to improve engraftment for human HSC transplantation, and 2) improving engraftment of transduced HSC for chemoprotective human cancer gene therapy.
